newsfilter
← Latest News
GlobeNewswire·

Novan Reports Third Quarter 2022 Financial Results and Provides Corporate Update

– Rhofade prescriptions increased 37% for third quarter year-to-date from prior year – – Continued progress toward submission of berdazimer gel, 10.3% (SB206) New Drug Application (NDA), targeted around the end of